Silvia Fanaro

Dr. Silvia Fanaro


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Early Human Development
Verified
Journal Article
Closed access
SFSilvia Fanaro
Silvia Fanaro

1 January 2009 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SFSilvia Fanaro
Silvia Fanaro
BMBerit Marten
Berit Marten
RBRossana Bagna
Rossana Bagna
VVVittorio Vigi
Vittorio Vigi
CFClaudio Fabris
Claudio Fabris
EBEnrico Bertino
Enrico Bertino

1 October 2005 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
SFSilvia Fanaro
Silvia Fanaro
GBGünther Boehm
Günther Boehm
JGjohan Garssen
johan Garssen
JKJan Knol
Jan Knol
FMFabio Mosca
Fabio Mosca
VVVittorio Vigi
Vittorio Vigi

20 September 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
FMFrancesca Miselli
Francesca Miselli
RCRiccardo Cuoghi Costantini
Riccardo Cuoghi Costantini
RCRoberta Creti
Roberta Creti
FSFrancesca Sforza
Francesca Sforza
SFSilvia Fanaro
Silvia Fanaro
ABAlberto Berardi
Alberto Berardi
The widespread use of intrapartum antibiotic prophylaxis (IAP) to prevent group B streptococcus (GBS) early-onset sepsis (EOS) is changing the epidemiology of EOS. Italian prospective area-based surveillance data (from 1 January 2016 to 31 December 2020) were used, from which we identified 64 cases of culture-proven EOS (E. coli, n = 39; GBS, n = 25) among 159,898 live births (annual incidence rates of 0.24 and 0.16 per 1000, respectively). Approximately 10% of E. coli isolates were resistant to both gentamicin and ampicillin. Five neonates died; among them, four were born very pre-term (E. coli, n = 3; GBS, n = 1) and one was born full-term (E. coli, n = 1). After adjustment for gestational age, IAP-exposed neonates had ≥95% lower risk of death, as compared to IAP-unexposed neonates, both in the whole cohort (OR 0.04, 95% CI 0.00–0.70; p = 0.03) and in the E. coli EOS cohort (OR 0.05, 95% CI 0.00–0.88; p = 0.04). In multi-variable logistic regression analysis, IAP was inversely associated with severe disease (OR = 0.12, 95% CI 0.02–0.76; p = 0.03). E. coli is now the leading pathogen in neonatal EOS, and its incidence is close to that of GBS in full-term neonates. IAP reduces the risk of severe disease and death. Importantly, approximately 10% of E. coli isolates causing EOS were found to be resistant to typical first-line antibiotics.

1 December 2007 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SFSilvia Fanaro
Silvia Fanaro
GBGloria Borsari
Gloria Borsari
VVVittorio Vigi
Vittorio Vigi

8 September 2012 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
SFSilvia Fanaro
Silvia Fanaro
Postnatal growth restriction and failure to thrive is a major issue in preterm, especially extremely low-birth-weight infants. Optimization of enteral nutrition, without increasing the risk of necrotizing enterocolitis (NEC), has thus become a priority for the neonatologist, who often has to face the challenge of interpreting the clinical and prognostic significance of common and aspecific signs of feeding intolerance (FI). The neonatologist often prescribes enteral nutrition as if walking on a tightrope between the purposed attainment of full enteral feeding and the fear of NEC. Despite advances in neonatal intensive care, NEC still remains one of the leading causes of mortality (15–30%) and morbidity in very-low-birth-weight infants. However, the relationship between FI and NEC remains unknown. Feeding intolerance often leads to discontinuation of enteral feeds, delayed attainment of full enteral feeding and prolongation of hospitalization. Strategies aimed at preventing and/or treating episodes of feeding intolerance are diverse and not always supported by scientific evidence.